Nonlinear Relationship Between Homocysteine and Mild Cognitive Impairment in Early Parkinson's Disease: A Cross-Sectional Study
Qingrong Ouyang,Lei Xu,Yunwei Zhang,Luwen Huang,Linlin Li,Ming Yu
DOI: https://doi.org/10.2147/ndt.s460938
IF: 2.989
2024-05-01
Neuropsychiatric Disease and Treatment
Abstract:Qingrong Ouyang, Lei Xu, Yunwei Zhang, Luwen Huang, Linlin Li, Ming Yu Department of Neurology, Suining Central Hospital, Suining, 629000, People's Republic of China Correspondence: Ming Yu, Tel +86 18008258574, Email Background: Cognitive impairment, a prevalent non-motor symptom in advanced Parkinson's disease (PD), has been associated with hyperhomocysteinemia, an important risk factor for PD progression and cognitive decline in PD. However, evidence regarding the association between homocysteine (Hcy) and cognitive function during early PD remains insufficient. Therefore, this study aims to examine the correlation between Hcy levels and cognitive function in the early stage of PD. Methods: The study included 218 individuals in the early stages of PD who were consecutively admitted to the Suining Central Hospital Neurology Department. All the individuals completed the Parkinson's Disease Cognitive Rating Scale (PD-CDR). The Unified Parkinson's Disease Rating Scale part III (UPDRS-III) was employed for measuring the severity of motor symptoms, while the Hoehn-Yahr scale was used to measure the clinical symptom stage. Fasting venous blood samples were also drawn to measure the Hcy concentration, red blood cell folate, and vitamin B12. Results: In this cross-sectional study, 47 (21.5%) patients with PD showed cognitive dysfunction. The serum Hcy levels were significantly higher in the cognitive impairment PD (PDCI) group compared with the cognitive normal PD group (P< 0.001). The Generalized Additive Model (GAM) analysis revealed a nonlinear relationship between Hcy and the risk of PDCI. Multiple logistic regression analyses demonstrated a positive relationship between elevated Hcy and the risk of PDCI in the fully adjusted model ([OR]:3.1, 95% CI, 1.1– 8.5, P=0.028). Segmented linear regression analysis showed that when Hcy levels were above 17.7 umol/l, the risk of PDCI increased by 1.6 times for every 1 unit elevated in Hcy (95% CI:1.1– 2.2, P=0.008). Conclusion: This study revealed a nonlinear positive correlation between the risk of PDCI and elevated serum Hcy levels in early PD patients, suggesting hyperhomocysteinemia as one of the treatable factors for cognitive impairment in the early stages of PD. Keywords: homocysteine, early Parkinson's disease, cognitive impairment, relationship Parkinson's disease dementia (PDD) is a widely recognized non-motor symptom in the advanced stages of PD, the cumulative incidence of PDD in PD patients suffering for more than 10 years is 75%. 1 It encompasses a spectrum of cognitive impairments across domains, including memory, attention, executive functioning, and visuospatial abilities. These cognitive impairments significantly affect social functioning and overall quality of life for individuals coping with PD. The pre-dementia stage comprises subjective cognitive impairment and mild cognitive impairment (MCI) 2, MCI not only serves as a significant risk factor for the development of early PDD, 3 but it is also recognized as a favorable stage for cognitive intervention therapy. However, it is often overlooked by clinicians, thereby resulting in missed opportunities for proactive interventions. According to a recent meta-analysis, the prevalence of MCI in PD patients is up to 40%. 4 Previous studies showed that around 20–40% of patients newly diagnosed with PD present with MCI. 5,6 Discrepancies in reported prevalence rates may arise from the diverse of assessment tools employed. 7 In conclusion, early diagnosis and intervention for MCI are crucial for preventing and minimizing its progression to PDD, suggesting an urgent need for exploring treatable risk factors. Elevated plasma Hcy levels may serve as a significant potential risk factor for PD-MCI. They have been observed not only in the general elderly population with cognitive impairment, 8 but also associated with conditions such as vascular cognitive impairment and Alzheimer's disease. 9,10 Recently, Fan et al have extensively reviewed the association of Hcy with the development and progression of PD. 11 The use of levodopa (L-dopa) has been found to elevate Hcy plasma levels, 12 therefore, it can potentially pose a risk for PDCI. However, the existing studies reporting on the relationship between Hcy levels and PDCI present contradictory findings. Several reports have documented a decline in cognitive function among PD patients with hyperhomocysteinemia. 13–18 As early as 2004, O'Suilleabhain et al conducted a study on a group of PD patients with a mean duration of 3.6 years, the results revealed that PD patients with coexisting hyperhomocysteinemia exhibited poorer cognitive function. 18 Recently, a l -Abstract Truncated-
psychiatry,clinical neurology